exclude-all-tiles

Hiding in plain sight – a case-based overview of amyloidosis

8 January 2026

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

Amyloidosis: a comprehensive guide for the cardiovascular team

8 January 2026

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

Protected: Rapid up-titration of heart failure therapies: practice strategies for adopting a STRONG-HF pathway in the UK

2 December 2025

Sponsored

Dr Rajiv Sankaranarayanan, Consultant Cardiologist, University Hospitals Liverpool is joined by Dr Parin Shah, Consultant Cardiologist, Swansea Bay University Health Board and Matthew Sunter, Lead Heart Failure Nurse, St. George's University Hospital, London as they share how they’ve implemented and adapted the STRONG-HF¹ pathway to improve heart failure care. They discuss early patient identification, rapid optimisation, and collaborative follow-up models tailored to local needs. Through shared learning and teamwork across disciplines, each centre has refined its approach to deliver more efficient, patient-centred heart failure management.